Literature DB >> 1480034

Latent collagenase and gelatinase from human neutrophils and their activation.

H Tschesche1, V Knäuper, S Krämer, J Michaelis, R Oberhoff, H Reinke.   

Abstract

Procollagenase M(r) 85,000 (SDS-PAGE) was purified from buffy coat to homogeneity and represents a stable single polypeptide chain forming the entire proenzyme. The procollagenase can be activated by various proteinases, e.g. trypsin, chymotrypsin, cathepsin G, kallikrein and stromelysin and by different mercurial compounds. Proteolytic conversion of the latent enzyme to the active form by chymotrypsin is accompanied by a molecular weight reduction to an apparent M(r) 64,000. This active enzyme lacks the first 79 N-terminal residues. Activation by trypsin leads to a latent intermediate of apparent M(r) 70,000, lacking 48 N-terminal residues. The active enzyme is therefore generated upon prolonged incubation with trypsin by further cleavage of 22 N-terminal residues. Another latent intermediate form with apparent M(r) 69,000 is generated from the proenzyme upon incubation with leukocyte elastase by N-terminal cleavage of 53 or 64 residues, respectively. However, latent collagenase cannot be activated by plasmin. Activation by different mercurial compounds finally results in the formation of active collagenase with apparent M(r) 64,000. In contrast to the proenzyme, active collagenase can autolyse to give active M(r) 57,000 and 45,000 intermediates and two M(r) 28,000 fragments. Purification of latent leukocyte gelatinase yields three final products with apparent M(r) 98,000, 125,000 and 220,000 (SDS-PAGE; non reduced). Upon reduction, only the M(r) 98,000 form can be detected. The latent gelatinase can be activated in a similar manner as collagenase. Proteolytic activation by trypsin leads after N-terminal cleavage to an active gelatinase with sequence homology to leukocyte collagenase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1480034

Source DB:  PubMed          Journal:  Matrix Suppl        ISSN: 0940-1199


  7 in total

1.  Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases.

Authors:  A Matsuzaki; A Janowska-Wieczorek
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase.

Authors:  J H Verheijen; N M Nieuwenbroek; B Beekman; R Hanemaaijer; H W Verspaget; H K Ronday; A H Bakker
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

3.  Hyperbaric oxygen effect on MMP-9 after a vascular insult.

Authors:  Francis J Cummins; Laurie J Gentene
Journal:  J Cardiovasc Transl Res       Date:  2010-09-08       Impact factor: 4.132

4.  Identification of CITED2 as a negative regulator of fracture healing.

Authors:  Jonathan Y Lee; Peter J Taub; Liang Wang; Amelia Clark; Ling L Zhu; Edward R Maharam; Daniel J Leong; Melissa Ramcharan; Zhengzhi Li; Zhonghou Liu; Yuan-Zheng Ma; Li Sun; Mone Zaidi; Robert J Majeska; Hui B Sun
Journal:  Biochem Biophys Res Commun       Date:  2009-07-14       Impact factor: 3.575

5.  Effects of Artemisia annua L. Essential Oil on Osteoclast Differentiation and Function Induced by RANKL.

Authors:  Wen Sun; Guangyue Yang; Fang Zhang; Chenguo Feng; Mingjie Liang; Pengfei Jia; Zhongliang Zhao; Hailing Guo; Yongfang Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-07       Impact factor: 2.650

6.  Identification of Key Genes and Pathways in Peripheral Blood Mononuclear Cells of Type 1 Diabetes Mellitus by Integrated Bioinformatics Analysis.

Authors:  Xing Li; Mingyu Liao; Jiangheng Guan; Ling Zhou; Rufei Shen; Min Long; Jiaqing Shao
Journal:  Diabetes Metab J       Date:  2022-04-01       Impact factor: 5.893

7.  AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways.

Authors:  Longxiang Huang; Qin Ye; Chunlin Lan; Xiaohui Wang; Yihua Zhu
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.